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ABSTRACT 
Disturbances in melatonin—the neurohormone that signals environmental 
darkness as part of the circadian circuit of mammals—have been implicated in various 
psychopathologies in humans.  At present, experimental evidence linking prenatal 
melatonin signaling to adult physiology, behavior, and gene expression is lacking.  We 
hypothesized that administration of melatonin (5 mg/kg) or the melatonin receptor 
antagonist luzindole (5 mg/kg) to rats in utero would permanently alter the circadian 
circuit to produce differential growth, adult behavior, and hippocampal gene expression 
in the male rat.  Prenatal treatment was found to increase growth in melatonin-treated 
animals.  In addition, subjects exposed to melatonin prenatally displayed increased 
rearing in the open field test and an increased right turn preference in the elevated plus 
maze.  Rats administered luzindole prenatally, however, displayed greater freezing and 
grooming behavior in the open field test and improved learning in the Morris water maze.  
Analysis of relative adult hippocampal gene expression with RT-PCR revealed increased 
expression of brain-derived neurotrophic factor (BDNF) with a trend toward increased 
expression of melatonin 1A (MEL1A) receptors in melatonin-exposed animals whereas 
overall prenatal treatment had a significant effect on microtubule-associated protein 2 
(MAP2) expression.  Our data support the conclusion that the manipulation of maternal 
melatonin levels alters brain development and leads to physiological and behavioral 
abnormalities in adult offspring.  We designate the term circadioneuroendocrine (CNE) 
axis and propose the CNE-axis hypothesis of psychopathology.
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INTRODUCTION 
The Circadian Circuit 
Melatonin, the hormone that encodes information about daily rhythms in 
mammals, has been implicated in various psychopathologies in humans.  Changes in 
melatonin secretion have been found in depression (for a review see Srinivasan et al. 
2006), Alzheimer’s disease and Parkinson’s disease (for a review see Srinivasan et al. 
2006), schizophrenia (for a review see Sandyk et al. 1990), and other psychiatric illnesses 
(for a review see Pacchierotti et al. 2001).  Despite indications that this neurohormone is 
important for proper brain function, the physiology of its impact on the brain is not 
clearly understood. 
Melatonin release displays rhythmic behaviors with a period of approximately 24 
hours in response to the circadian pacemaker (Figure 1) (Refinetti 2006).  In mammals, 
the circadian pacemaker is controlled by clock genes in the suprachiasmatic nucleus 
(SCN) of the hypothalamus (Figure 2) (for a review see Okamura 2004).  Daily 
fluctuations in the activity of the SCN can be altered by light from the environment via 
projections from retinal ganglion cells along the retinohypothalamic path.  In addition, 
outputs from the SCN project indirectly to the pineal gland, the primary brain region 
responsible for the production of melatonin.  The pineal releases melatonin with a nightly 
peak in response to input from the SCN to impact cells throughout the body.  In addition, 
the SCN responds to melatonin secretion by the pineal via melatonin receptors in 
membranes of its cells.  This feedback loop involving visual inputs and melatonin  
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Figure 1.  Simplified schematic of the circadian circuit responsible for daily rhythm 
of activity in mammals (Adapted from Refinetti 2006).  Light at the retina induces 
signaling at glutamatergic synapses by retinal ganglion cells projecting to the 
suprachiasmatic nucleus along the retinohypothalamic path.  In addition, the 
intergeniculate leaflet of the thalamus receives signals from the retina and relays this 
information to the suprachiasmatic nucleus via neuropeptide Y synapses, and the raphe 
nuclei also communicate other environmental information to the suprachiasmatic nucleus 
via serotonergic synapses.  The suprachiasmatic nucleus, which contains the primary 
circadian molecular clock, processes these inputs and elicits release of melatonin by the 
pineal gland in addition to projecting to other brain regions.  Melatonin produced by the 
pineal gland is released into circulation in the blood and cerebrospinal fluid in response to 
this stimulation.  In addition to feeding back to the suprachiasmatic nucleus, melatonin 
also modulates release of growth hormone by the pituitary gland by an as yet unidentified 
mechanism.  Both melatonin and growth hormone affect the hippocampus and other brain 
regions in a circadian fashion. 
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Figure 2.  Simplified model of the oscillatory molecular clock gene network in cells 
of the suprachiasmatic nucleus of mammals (adapted from Okamura 2004).  The 
mPER1 and mPER2 genes are expressed along with other ccg (clock controlled genes) to 
produce various proteins that dimerize.  These mPER-mCRY dimers inhibit CLOCK-
BMAL1 protein dimer function and indirectly promote expression of the Bmal1 gene.  
Over several hours, mPER1 and mPER2 expression declines, but concentration of 
CLOCK-BMAL1 dimers gradually begins to rise again.  These dimers bind E-boxes and 
promote expression of mPER1, mPER2, and ccg to complete the feedback loop. 
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secretion entrains the sleep/wake cycle of mammals to their environment.  We shall refer 
to the neurohormonal feedback loop involving the SCN, pineal, and associated structures 
as the circadian circuit. 
Within cells of the pineal gland in mammals, melatonin is produced by a multi-
step biosynthetic pathway (Figure 3) (for reviews see Axelrod 1970; Simonneuax et al. 
2003).  5-Hyrdoyxytryptophan is synthesized from tryptophan by tryptophan hydroxylase 
(TPOH).   Aromatic amino acid decarboxylase (AAAD) converts 5-hydroxytryptophan to 
serotonin, and acetylation of serotonin by arylalkylamine N-acetyltransferase (AA-NAT) 
produces N-acetylserotonin.  Finally, hydroxyindole-O-methyltransferase (HIOMT) 
produces melatonin from N-acetylserotonin.  Interestingly, children with autism spectrum 
disorder and their unaffected parents were more likely to have a mutation in the HIOMT 
gene and concomitant reduction in melatonin production compared to controls (Melke et 
al. 2008).  The synthetic melatonin receptor antagonist luzindole has a structure similar to 
that of melatonin but contains an additional benzyl group (Dubocovich 1988). 
 
Melatonin, Development, and Pathology 
Melatonin produced by the circadian circuit has broad impacts throughout the 
body.  There is evidence that melatonin may influence secretion of growth hormone by 
the pituitary by an as yet unidentified mechanism.  The nightly peak in melatonin may be 
involved in the timing of growth hormone production (Brandenberger et al. 2004).  
Human subjects administered 10 mg of melatonin showed an increase in serum growth 
hormone in response to the drug (Valcalvi et al. 1993), however, earlier studies found  
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Figure 3.  Structures of molecules in the melatonin biosynthetic pathway in the 
pineal gland (a) (adapted from Simonneaux et al. 2003) and of the melatonin 
receptor antagonist luzindole (b).  Structures of all molecules shown contain indole 
groups composed of a pyrrole ring attached to a benzene ring.  In pinealocytes, 5-
hydroxytryptophan is synthesized from tryptophan by tryptophan hydroxylase (TPOH).  
Aromatic amino acid decarboxylase (AAAD) then converts 5-hydroxytryptophan to 
serotonin, and acetylation of serotonin by arylalkylamine N-acetyltransferase produces 
N-acetylserotonin.  Finally, hydroxyindole-O-methyltransferase (HIOMT) produces 
melatonin from N-acetylserotonin.  The synthetic melatonin receptor antagonist luzindole 
has a structure similar to that of melatonin but contains an additional benzyl group. 
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that melatonin has an inhibitory effect on growth hormone release in both humans 
(Smythe et al. 1974 a) and rats (Smythe et al. 1973).  Insertion of melatonin implants in 
3- to 4-month old heifers for 5 weeks in early summer induced precocious puberty in 
heifers (Tortonese et al. 1992), and pineal gland tumors that reduce melatonin secretion 
from the pineal gland during development elicited precocious puberty in humans (Cohen 
et al. 1964).  Interestingly, precocious puberty was found to be a predictor for a subtype 
of schizophrenia in women (Cohen et al. 1999). 
Because melatonin release by the circadian circuit is influenced by light, 
melatonin secretion is affected by seasonal variation in light patterns.  Seasonal changes 
in melatonin profiles regulate reproduction in many mammals (for a review see Arendt 
1998).  Nightly peaks of melatonin in adult (Luboshitzky et al. 1998) and infant (Sivan et 
al. 2001) humans may be greatest when photoperiods are the longest.  Moreover, risk of 
developing schizophrenia is greater for individuals born during winter and early spring at 
greater latitudes (Davies et al. 2003), when maternal nightly melatonin secretion during 
the third trimester is lowest.  A seasonal correlation between birth date and adult disease 
has been found in various studies on psychiatric disorders in humans (for a review see 
Torrey et al. 1997).  Explanations for this variation have been proposed, but the causes 
have yet to be identified. 
Evidence in various animal models suggests a role for melatonin in brain 
development.  Reduced prenatal melatonin by pinealectomy was associated with 
increased signs of depression in Siberian hamster offspring (Workman et al. 2008).  In 
addition, studies using cell cultures suggest a possible role for melatonin during 
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embryonic development.  Melatonin inhibits apoptosis in U973 human monocytic cells 
(Radogna et al. 2006), and it has been found to reduce damage to rat hepatoma cells by 
free radicals via its function as a free radical scavenger (Kimball et al. 2008).  In addition 
to its effects on cell maintenance, melatonin has been found to affect cell growth.  
Melatonin promotes polymerization of tubulin and production of neurites in cells in vitro 
(Meléndez et al. 1996).  Melatonin also increases the rate of cell proliferation in zebrafish 
embryos (Danilova 2004), and it promotes differentiation but not proliferation of adult 
hippocampal neurons in culture (Moriya et al. 2007). 
Melatonin receptors are distributed in various brain regions in the human fetus, 
including the hypothalamus, thalamus, and meninges (Thomas et al. 2002) and are more 
widely distributed in the brains of fetal and neonatal rats compared to adults (Zitouni et 
al. 1995).  Moreover, maternal pinealectomy reduces melatonin receptor number in the 
SCN, pituitary, and thalamic structures of rat neonates (Zitouni et al. 1995). 
Signaling via these melatonin receptors in the fetal brain may cause permanent 
changes in the circadian circuit.  Cocaine was found to cause long-term changes in 
expression of clock genes in zebrafish embryo, and this effect was reversed by 
administration of melatonin (Shang et al. 2007).  In addition, prenatal melatonin 
reduction was found to alter the clock gene expression in the SCN of capuchin monkeys 
(Torres-Farfan et al. 2006) and treatment with prenatal melatonin altered postnatal 
photoperiodic traits of young meadow voles (Lee et al. 1989).  These studies indicate that 
melatonin concentrations in utero may affect the function of the circadian circuit not only 
in the womb but also after birth. 
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Melatonin is also important in the brain postnatally, and melatonin receptors have 
been found in the adult rat hippocampus (Mushoff et al 2002).  In fact, melatonin 
administration altered long-term potentiation and ultimately synaptic plasticity of 
hippocampal cells from CD-1 mice (El-Sherif et al 2003) and long-term treatment with 
melatonin increased NMDA receptor concentrations in the rat hippocampus (Sutcu et al 
2006).  Deletion of the gene for the MT2 melatonin receptor in mice produced memory 
deficits in habituation to the elevated plus maze (Larson et al 2006) and treatment with 
melatonin reduced hippocampal degeneration in a mouse model of Alzheimer’s disease 
(Cheng et al 2008).  Thus, regular secretion of melatonin in adulthood may contribute to 
maintenance of proper hippocampal function. 
 
Hippocampus, Limbic System, and HPA Axis 
 Changes in hippocampal morphology have been found in various psychiatric 
disorders.  For example, individuals with autism from ages 2 to 42 years were found to 
have reduced volume in the area dentata of the hippocampus (Saitoh et al. 2001), and 
three- to four-year-old children with autism have been found to have significant changes 
in hippocampal shape by large-deformation high-dimensional brain mapping (Dager et al. 
2007).  Moreover, enlarged volume of the left hippocampus was identified not only in 
children and adults with autism but also in parents of children with autism (Rojas et al. 
2004), and changes in hippocampal structure have been found in individuals with 
schizophrenia.  High-dimensional brain mapping revealed morphological deformations in 
regions of the hippocampus projecting to the prefrontal cortex in drug-naïve patients with 
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schizophrenia (Csernansky et al. 1998), whereas Rajarethinam et al. (2001) found no 
significant difference in hippocampal size between individuals with schizophrenia and 
controls but did find a correlation between shape of left hippocampal subregions and 
symptoms in male subjects.  Meta-analyses reveal a general reduction in hippocampal 
volume in schizophrenia (McCarley et al. 1999; Nelson et al. 1998). 
 The hippocampus has been identified to have various roles in humans and other 
mammals.  In elderly human subjects, hippocampal head volume was found to be 
negatively correlated with age (Chen et al. 2010).  Specifically, right hippocampal tail 
volume was connected to spatial memory on the Groton Maze Learning Test, and left 
hippocampal volume was associated with deficits in verbal memory.  In addition, adult 
males ages 18-31 who were more resistant to forgetting in a monetary incentive delay 
task displayed greater activation in the left posterior hippocampus via fMRI (Kuhl et al. 
2010), and human subjects with amnesia resulting from bilateral hippocampal insult 
displayed greater difficulty imagining scenarios compared to controls (Hassabis et al. 
2007).  A recent review argued for roles of the hippocampus in imagination and 
prediction (Buckner 2010).  Moreover, the hippocampus has been implicated in spatial 
learning across mammalian species (for a recent letter see Amrein et al. 2009; for a 
review see El Falougy et al. 2006). 
More generally, the hippocampus is considered part of the limbic system, a brain 
circuit involved in emotion (for symposium see Nakano 1998; for review see Sapolsky 
2003).  The limbic system is capable of activating the hypothalamic-pituitary-adrenal 
(HPA) axis—the neuroendocrine mediator of the stress response in mammals—in 
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response to environmental stimuli (for a review see Engelmann et al. 2004).  Within this 
circuit, the hypothalamus releases corticotrophin-releasing hormone (CRH) in response to 
signals from other brain regions (Figure 4) (for a review see Tsigos et al. 2002) and CRH 
elicits release of adrenocorticotropic hormone (ACTH) from the anterior pituitary.  
ACTH promotes release of corticosteroids—including cortisol—from the adrenal 
cortices, and these corticosteroids inhibit further release of hormones by the 
hypothalamus and pituitary. 
Dysregulation of the limbic system and HPA axis has been found in various 
psychiatric disorders.  Patients with resistant schizophrenia were found to have a higher 
level of serum cortisol, and these levels were correlated with negative symptoms of the 
disorder (Zhang et al. 2005).  Women with postpartum depression were found to have 
increased ACTH but reduced cortisol relative to controls (Jolley et al. 2007).  
Responsiveness of cortisol release to negative events was found to be blunted in 
individuals with major depressive disorder, but no basal difference in salivary cortisol 
levels was observed (Peeters et al. 2003).  Moreover, children with autism showed greater 
variability in circadian salivary cortisol profiles relative to controls (Corbett et al. 2008).  
Thus, dysregulations of the HPA axis are connected with psychiatric disorders. 
 
Serotonin Receptors 
Evidence implicates the HPA axis in regulation of hippocampal serotonin (5-
hydroxtrypatamine or 5HT) receptors (for a review see Leonard 2005).  At present, 14 
subtypes of serotonin receptors have been identified in mammals (for a review see  
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Figure 4.  Simplified schematic of the hypothalamic-pituitary-adrenal (HPA) axis 
(adapted from Tsigos et al. 2002).  The hippocampus and other regions of the limbic 
system elicit release of corticotropin-releasing hormone (CRH) from the hypothalamus in 
response to stress.  CRH promotes release of adrenocorticotropic hormone (ACTH) by 
the anterior pituitary, and ACTH causes the adrenal cortices to release corticosteroids 
including cortisol (CORT) into the bloodstream.  CORT inhibits further release of ACTH 
and CRH in addition to impacting the hippocampus and other brain regions. 
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Nichols et al. 2008).  All serotonin receptor subtypes except for 5HT3 receptors are G-
protein-coupled receptors (GPCRs).  In particular, serotonin GPCRs are of the type A 
family of rhodopsin-like receptors (Fredriksson et al. 2003) while the 5HT3 receptor is a 
ligand-gated ion channel (Maricq et al.  1999) (for a review of 5HT receptors see Barnes 
et al. 1999). 
Research also indicates potential differential involvement of serotonin (5-
hydroxytryptamine or 5HT) receptor subtypes in psychopathology.  Serotonin receptor 
concentrations have been found to be altered in the hippocampus of individuals with 
severe psychiatric illness (Knable et al. 2004).  In particular, it was found that 5HT1A 
expression was lower in the hippocampus of individuals with major depressive disorder 
while subjects with schizophrenia and bipolar disorder had increased 5HT1B expression 
and decreased 5HT2A expression in the hippocampus (López-Figueroa et al. 2004).  
Since melatonin may also play a role in these psychopathologies, investigation of the 
effects of melatonin on the serotonergic system is warranted. 
Corticosteroids have been found to be involved in the regulation of hippocampal 
5HT1A receptor expression.  In particular, adrenalectomy of Sprague-Dawley rats 
increased 5HT1A mRNA expression in the hippocampus 1 day and 7 days after surgery 
and this change could be prevented by administration of cortisol at surgery (Chalmers et 
al. 1993).  Activation of 5HT1A receptors in the rat hippocampus inhibits adenylyl 
cyclase (Okada et al. 1989), and administration of serotonin and the 5HT1A receptor 
agonist NAN-190 to Wistar rat hippocampal CA1 cells in culture resulted in reduced 
excitatory post-synaptic potentials (EPSPs) (Schmitz et al. 1995).  5HT1A agonists were 
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unable to elicit hyperpolarization in mouse hippocampal neurons from mice lacking the 
gene for G protein-coupled inwardly rectifying K
+
 channel 2 (GIRK2) (Luscher et al. 
1997).  In addition to their involvement in serotonergic transmission, 5HT1A receptors 
are also involved in noradrenergic transmission in the hippocampus.  In particular, 
activation of hippocampal 5HT1A receptors elicited activation of noradrenergic pathways 
postsynaptically in rats (Hajós-Korcsok et al. 1999).  In addition, the increase in 
acetylcholine release in response to administration of the 5HT1A agonist 8-OH-DPAT 
was prevented by administration of the 5HT1A receptor antagonist WAY-100135 (Nakai 
et al. 1998). 
In contrast, corticosteroids were not found to regulate expression of 5HT1B 
mRNA in adrenalectomized male Sprague-Dawley rats (Neumaier et al. 2000).  In CHO 
cells, 5HT1B receptors were found to inhibit adenylyl cyclase and increase activity of 
ERK2 (Mendez et al. 1999).  Moreover, signaling via 5HT1B receptors reduced serotonin 
release in the rat hippocampus in vivo (Martin et al. 1992), suggesting a role for this 
receptor subtype as an autoreceptor.  This receptor subtype has also been found to inhibit 
cholinergic pathways in the rat hippocampus (Maura et al. 1986). 
5HT2A receptors have distinct roles in the stress response.  NIH3T3 fibroblasts 
expressing rat 5HT2A receptors were found to release the endocannabinoid 2-
arachidonoyl glycerol via activation of phospholipase C (PLC) (Parrish et al. 2006).  In 
cultured astrocytes from newborn rat cerebral cortex, 5HT2A receptor activation elicited 
Ca
2+
 influx via ligand-gated ion channels (Hagberg et al. 1998).  Moreover, hippocampal 
granule cells from male Sprague-Dawley rats administered serotonin induced 
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depolarization and this response was reduced by the 5HT2A receptor antagonist MDL 
100,907 (Piguet et al. 1994).  The reduction of BDNF expression in the hippocampus 
observed in response to immobilization stress in male Sprague-Dawley rats was also 
attenuated by administration of the 5HT2A receptor antagonist MDL, 100,907 prior to 
testing (Vaidya et al. 1999). 
 
Brain Derived Neurotrophic Factor 
Brain derived neurotrophic factor (BDNF) is a protein signaling molecule known 
for its promotion of growth and survival of neurons in the hippocampus (for a review see 
Binder et al. 2004). Activation of BDNF’s tropomyosin-related kinase B receptor (TrkB) 
increased activity of synaptic proteins in rat cortical neurons in culture, and depletion of 
BDNF or inhibition of its receptor prevented this effect (Jia et al. 2008).  Activation of 
TrkB was also found to be required for long-term synaptic facilitation in Aplysia (Sharma 
et al. 2006).  Reduced levels of BDNF have been found in the serum of patients with 
schizophrenia (Toyooka et al. 2002), and BDNF has also been implicated in depression 
(for a review see Castrén et al. 2010).   
 
Microtubule-Associated Protein 2 
Microtubule-associated protein 2 is (MAP2) is one of several proteins involved in 
the cytoskeletal organization in dendrites (for a review see Farah et al. 2008), and 
increased expression of MAP2 has been found in the hippocampus of individuals with 
schizophrenia (Cotter et al. 2000).  Dendritic size was found to be reduced in cerebellar 
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tissue from MAP2-knockout mice, and cells from these animals displayed reduced PKA 
signal transduction (Harada et al. 2002).  Induction of long-term potentiation (LTP) in 
various hippocampal pathways increased expression of MAP2 mRNA (Roberts et al. 
1998), and application of NMDA—a glutamate agonist mediating LTP induction—to 
hippocampal granule cells also elicited increased expression of MAP2 mRNA in 
dendrites (Johnston et al. 1994). 
 
Spinophilin 
Another dendritic protein associated with the cytoskeleton, spinophilin or 
neurabin 2, is localized in the heads of dendritic spines (for a review see Sarrouilhe et al. 
2006).  Phosphorylation of spinophilin by protein kinase A (PKA) in vitro elicits its 
dissociation from actin filaments (Hsieh-Wilson et al. 2003).  Spinophilin also blocks a 
binding site of protein phosphatase 1 (PP1) without blocking its active site to direct the 
enzyme to particular substrates (Ragusa et al. 2010). Spinophilin-knockout mice showed 
reduced ability of PP1 to regulate AMPA and NMDA receptors resulting in inhibition of 
long-term depression in the caudotoputamen and reduced hippocampal size (Feng et al. 
2000).  This study also found increased numbers of dendritic spines in hippocampal cells 
from young spinophilin knockout mice relative to controls.  Interestingly, patients with 
schizophrenia and mood disorders showed similar reductions in spinophilin mRNA in the 
hippocampus via in situ hybridization (Law et al. 2004). 
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Growth Hormone Receptor 
Growth hormone receptor (GHR) is a cell membrane receptor (for a review see 
Postel-Vinay et al. 1995).  Fusion of ligand to this receptor elicited receptor dimer 
formation and signal transduction in CHO cells (Wilkinson et al. 2007).  Growth 
hormone administration enhanced excitatory post-synaptic potentials in slices of 
pyramidal neurons from the CA1 region of the hippocampus of male Sprague-Dawley 
rats (Mahmoud et al. 2006).  Although circulating growth hormone is secreted from the 
anterior pituitary, growth hormone production has also been detected in the hippocampus 
of Sprague-Dawley rats of both sexes, and growth hormone mRNA levels in this brain 
region increase in response to stress (Donahue et al. 2006). 
 
Melatonin Receptors 
Two primary types of melatonin receptors have been identified in various 
mammalian tissues, including the hippocampus (for a review see Pandi-Perumal et al. 
2008).  Both MEL1A (Brydon et al. 1999) and MEL1B (Reppert et al. 1995) receptors 
are from the G-protein-coupled-receptor family and are coupled to inhibition of adenylyl 
cyclase.  The C-terminal domain of both receptor subtypes is necessary for internalization 
(Sethi et al 2008).  Evidence suggests a role for melatonin receptors in hippocampal 
pathology.  For example, MEL1A receptor expression increased (Savaskan et al. 2002) 
and MEL1B receptor expression decreased (Savaskan et al. 2005) in the hippocampus of 
elderly patients with Alzheimer’s disease relative to controls. 
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Hypothesis 
 Our study was designed to test the hypothesis that increasing or decreasing 
prenatal melatonin signaling in male rattus norvegicus affects growth, hippocampal mass, 
anxiety- and depression-related behaviors, spatial learning, and memory in adult rats.  In 
addition, we hypothesized that prenatal treatment would produce differential adult 
hippocampal mRNA expression profiles for genes involved in regulating dendritic 
structure and function as well as neuron maintenance and cognitive function. 
 
MATERIALS AND METHODS 
Animals and Tissue Collection 
Eleven pregnant Sprague-Dawley dams were obtained from Hilltop Laboratories 
in two cohorts and randomly assigned to three treatment groups.  Three of the dams were 
injected with vehicle containing 50% (volume/volume) sterile, filtered DMSO (Sigma 
Aldrich, St. Louis, MO) in distilled water (i.e. 0.1 mL DMSO/kg dam per day), four were 
injected with 5 mg/kg melatonin (N-Acetyl-5-methoxytryptamine) (Sigma Aldrich), and 
four were injected with 5 mg/kg luzindole (N-Acetyl-2-benzyltryptamine) (BA 
Chemicals, London, UK), a nonselective melatonin receptor antagonist (Dubocovich 
1988).  All drugs were administered subcutaneously immediately before the dark cycle at 
1600 to 1800 hours as this is the time of maximal response to the drugs (Golombek et al. 
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1993).  Injections were given for 5 days from days 14 to 18 of gestation at a volume of 
0.05 to 0.06 mL per day.  Dams were housed individually. 
All animals were kept under controlled lighting (0600 to 1800 hours) and 
temperature (23ºC) with food and water ad libitum.  Food consisted of standard rat chow 
providing 3.85 kcal/g (dry wt), 19.2 gm% protein, 67.3 gm% carbohydrate, and 4.3 gm% 
fat (10 kcal% fat D12450B; Research Diets, New Brunswick NJ).  At birth, offspring 
were weighed and litters were culled to 10 young per dam while maintaining all healthy 
males. At weaning on postnatal day 21, male offspring were housed in pairs with a 
conspecific from the same treatment group.  Body mass per rat and food intake per cage 
were measured approximately every 5 to 7 days from weaning until sacrifice.  After 120 
days, half the animals were sacrificed at 0000 hours, and the rest were sacrificed at 1200 
hours.  The animals were momentarily placed in a pre-charged chamber of CO2 and 
subsequently decapitated by guillotine. Immediately following sacrifice, right and left 
hippocampi were quickly dissected from each brain, weighed, and rapidly frozen with 
liquid nitrogen; and abdominal, retroperitoneal, and gonadal fat was excised. This 
research was conducted in accordance with the NIH Guide for Care and Use of 
Laboratory Animals, and all animal protocols used have been reviewed and approved by 
the Animal Care and Use Committee of Bucknell University. 
 
Behavioral Measures 
 After postnatal day 90, a staggered behavioral testing regimen was begun on adult 
subjects.  Animals from cohort one were subjected to tests in the following order: open 
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field test, forced swim test, elevated plus maze, and Morris water maze; cohort two 
subjects were tested as follows: Morris water maze, elevated plus maze, forced swim test, 
open field test.  All behavioral tests were recorded, and data was measured by computer 
with tracking software (ANY-Maze, Stoelting, Wood Dale IL).  Time inactive was found 
by subtracting time mobile, time rearing, and time grooming from total time.  Turn 
preference was calculated as follows:  
  








1  Turns ckwiseCounterclo
1  Turns Clockwise
log PreferenceTurn     (1) 
 Forced swim test.  The forced swim test is a measure of learned helplessness.  The 
learned helplessness hypothesis states that ―when events are uncontrollable the organism 
learns that its behavior and outcomes are independent‖ (Maier et al. 1976).  This 
behavioral construct includes ―motivational,‖ ―cognitive,‖ and ―emotional‖ components.  
Porsolt et al. (1978) developed the forced swim test to measure learned helplessness.  In 
the forced swim test, immobility in response to placement in an inescapable tank of water 
as evidenced by free floating is considered a sign of learned helplessness (West 1990).  
Although learned helplessness is a construct with respect to learning, changes in 
performance on learned helplessness tasks have been connected to depression (Sherman 
et al. 1982). 
 The protocol of Porsolt et al. (1978) was modified slightly for this study.  Animals 
were placed in translucent white plastic cylinders (45 cm height 35 cm diameter) 
containing 30 cm water (25 ±2 °C) in 160 lux light for 15 minutes without recording, and 
the tank was emptied between subjects.  Twenty-four hours later, animals were similarly 
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placed in tanks, and behavior was recorded for 5 minutes.  Time immobile was 
determined by tracking software at 50% sensitivity, and total distance travelled was also 
used as an indicator of immobility (Hedou et al. 2001). 
Open field test.  The open field test was originally created by Calvin Hall as a 
measure of fearfulness (Walsh et al. 1976).  In this test, the response of animal subjects to 
an open space from which they cannot escape is measured.  The test has been considered 
a measure of both ―emotionality‖ and ―exploratory behavior‖, although other constructs 
have been developed (Maier et al. 1988).  In addition, habituation of behavior in the 
testing environment occurs upon multiple trials, so learning is also involved (Bolivar et 
al. 2000).  The open field test is frequently used in pharmacological studies for the 
measurement of anxiety (Choleris et al. 2001, Prut et al. 2003, Ramos et al. 1997), 
although measures of general locomotor activity can also be obtained from the test 
(Maier et al. 1988).  The use of the test as a measure of anxiety is evidenced by the 
effects of anxiety drugs on behavior of rodents in the testing arena (Choleris et al. 2001).  
Rats spend more time in the center zone and less time in thigmotaxis (staying near the 
walls of the test arena) if they are less anxious (Prut et al. 2003).  However, responses 
upon repeated trials can vary by rat strain (Bolivar et al. 2000). 
A black testing arena (100 cm x 100cm x 40 cm) with an open top was used 
(Ramos et al. 1997).  Light reaching the arena was 65 lux at the center, 45 lux at the 
middle of the sides, and 30 lux in the corners.  Although various colors ranging from 
white to black have been used for the arena (Walsh et al. 1976), black was chosen for 
greater contrast of the rat with background (Walsh et al. 1976).  Although rats can be 
26 
 
placed in either the center or a corner of the arena at the start of the procedure, we placed 
them in the center (Ramos et al. 1997).  The arena was divided by the software into 25 
squares: 16 outer squares and 9 inner squares (Figure 5a).  While behavior has been 
recorded for various lengths of time, we did so for 5 minutes (Ramos et al. 1997).  While 
tracking software recorded most measures, human observers documented rearing and 
grooming behavior during testing using ―keys‖ within the software package.  Immobility 
detection was set at 75% sensitivity. 
Elevated plus maze.  The elevated plus maze is commonly used as a measure of 
anxiety in rodents (Hogg 1996).  Anxiety is measured by decreased entries to the open 
arms of the apparatus.  In particular, the decreased height or absence of walls on the open 
arms produces a fear response (Rodgers et al. 1997).  Moreover, time on open arms 
increases in response to anxiolytic drugs (Rodgers et al. 1997).  Others, however, have 
also included an approach/avoidance construct in measuring behavior in this test (Wall et 
al. 2001) by considering entries to the center of the apparatus. 
The protocol of Walf et al. (2007) was used with modifications.  Animals were 
placed in the center of the plus sign-shaped testing arena (arms 50cm long by 10 cm side 
with a 5 mm railing on the open arms) constructed of fiberboard coated with black acrylic 
paint and elevated 50 cm from the floor (Figure 5b).  Light reaching the apparatus was 13 
lux at the center, 25 lux on the open arms, and 3.5 lux in the closed arms.  Behavior of 
animals was recorded for 5 minutes with human observer present in the room behind a 
curtain.  Grooming and rearing behavior were recorded real-time by human observer 
using the tracking software package, and immobility detection was set at 75% sensitivity. 
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Figure 5.  Diagrams of testing arenas used for the open field test (a), elevated plus 
maze (b), and Morris water maze (c).  The open field testing arena was divided into 25 
squares with center zone and corner regions (a).  The elevated plus maze testing arena 
was divided into two closed arms with walls, two open arms without walls, and a central 
platform zone (b).  The Morris water maze testing arena was divided into quadrants with 
cardinal directions, and a hidden platform was located at the center of a memory region 
zone (c). 
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Animals that fell off the apparatus were returned to it and allowed to complete the testing, 
but data from these subjects was excluded from analysis (Walf et al. 2007).  Before each 
trial, the maze was cleaned with water containing detergent and allowed to dry.   
 Morris water maze.  The Morris water maze was developed by Richard G.M. 
Morris for the testing of spatial learning and memory in rats.  In particular, lesions in the 
various brain regions—including the hippocampus—impair performance on this test 
(d’Hooge et al. 2001).  In addition, the Morris water maze has also been used to measure 
cognitive deficits in models of a variety of neuropsychiatric disorders (d’Hooge et al. 
2001). 
The protocol of Vorhees et al. (2006) was used with the modifications.  A 
platform (19.5cm x 19.5 cm x 19.5 cm black cinderblock) was placed in a tank (58 cm 
height, 168cm diameter) painted black (Figure 5c).  At the center of the apparatus, light 
was 75 lux; at the walls, light was approximately 35 lux.  Cardinal coordinates were 
arbitrarily chosen so that the platform was located in the NW quadrant of the tank.  The 
tank was filled with water at 25 ±2 °C at the beginning of each testing day to 4 cm above 
the top of the cinderblock platform and emptied upon completion of all tests.  Geometric 
patterns were placed on three walls of the testing room as visual cues.  During the 5 days 
of the learning phase of the test, animals were placed in the tank facing the wall at one of 
each of the cardinal coordinates for 4 trials in a predetermined, randomly-selected order 
by cohort.  Latency to platform was recorded by tracking software.   A trial ended when 
the rat remained on the platform for 2 seconds or after 120 seconds.  Animals that did not 
find the platform in 120 seconds were placed on the platform.  Subjects were allowed to 
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rest on the platform for 15 seconds before the subsequent trial.  If a rat did not remain on 
the platform, it was placed back on the platform repeatedly for the duration of 15 
seconds.  Latencies for the 4 trials for per day were averaged.  Forty-eight hours after the 
completion of the learning phase of the test, animals were returned to the tank after 
removal of the platform for one trial.  Preference for the region of the former location of 
the platform was recorded for one 30-second trial in order to test memory retention. 
 
RNA Isolation, RT-PCR, and Data Analysis 
Total RNA was extracted from the left hippocampus of each subject with TRIzol 
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions, and after 
purification, total RNA was reverse transcribed with RETROscript (Ambion, Austin, TX) 
following producer’s recommendations. Real-time PCR was effected with SYBR Green 
Supermix (Bio-Rad, Hercules, CA) on an iCycler iQ Real Time PCR Detection System 
(Bio-Rad, Hercules, CA).  Primers were designed with the NCBI online database 
(www.ncbi.nlm.nih.gov) and Primer3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi).  Primer pair sequence specificities were confirmed via 
BLAST (Table 1), and all primers were obtained from MWG Oligo Synthesis (High 
Point, NC).  Real-time PCR was performed in 96-well optical plates with 0.05μM each of 
forward and reverse primers, cDNA from 2μg RNA input (diluted 1:50), and 12.5μL 
Supermix.  Target genes were amplified through the following thermocycling program: 
95ºC for 3’, 40 X 15‖ PCR cycles at 95ºC, 60ºC for 1’, and 55ºC for 1’. At the end of the 
program, 80 repeats of 15‖ each accompanied by a temperature ramp of 0.5ºC/repeat 
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Table 1. Primer sequences (GenBank/NCBI) used in real-time PCR                                                                                                                                                        
------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Primer ID  Primer Sequence  5’—3’   Accession No.  Length, nt 
------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
18S  Fwd: AAACGGCTACCACATCCAAG  M11188     76 
Rev: GGCCTCGAAAGAGTCCTGTA            
 
5HT1A  Fwd: TGTTGCTCATGCTGGTTCTC  NM 012585    76 
  Rev: CCGACGAAGTTCCTAAGCTG            
 
5HT1B  Fwd: CTGGTGTGGGTCTTCTCCAT  NM 022225    84 
  Rev:  GTTCACAAAGCAGTCCAGCA            
 
5HT2A  Fwd: CTGCTGGGTTTCCTTGTCAT   NM 017254    93 
  Rev: ATCCAGATCGCACAGAGCTT            
 
BDNF  Fwd: AGAGATCCAGCCCTGAGACA  NM012513.3    98 
  Rev: TCACCACATGGAAGGGTCTT            
 
MAP2  Fwd: ACGTTCGCTTGAAAAGGAGA  NM013066.1    89 
  Rev: CATGACGTTGATTCGTTTGG            
 
SPN  Fwd: GCAGGATCCAAGTGAACGAT  NM      96 
  Rev: CGGTTTGGTGTTCCTAAGCA            
 
GHR  Fwd: CCTGATCCGCCCATTGGCCT  NM017094    76 
  Rev: GCGGTGGCTGCCAACTCACT            
 
MEL1A  Fwd: GAGCGGGGTAAGGGGCAGGA  NM053676    82 
  Rev:  AGTGCCCAGCTCTGCTTGCG            
 
MEL1B  Fwd: CCGAGCCTGCAGTCAGTGGC  NM001100641    76 
  Rev:  GGGCACCAAGGCCACCAGAG            
 
--------------------------------------------------------------------------------------------------------------------------------------------------------                                                                                                                                           
Final concentration of each primer was 1μM 
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 were performed during which dissociation curve data were collected to verify that only 
target sequences were amplified. 
The following genes were amplified from hippocampus-derived cDNA: three 
serotonin (5-hyroxytryptamine or 5HT) receptor subtypes (5HT1A, 5HT1B, and 
5HT2A), brain-derived neurotrophic factor (BDNF), microtubule-associated protein 2 
(MAP2), spinophilin (SPN), melatonin receptor subtypes 1A and 1B (MEL1A and 
MEL1B), and growth hormone receptor (GHR).  Each gene was co-amplified with a 
standard housekeeping gene, 18S ribosomal RNA, to control for pipetting error. 
A real-time PCR was conducted for each primer pair in which cDNA samples 
were substituted with dH20 to verify that exogenous DNA was not present. Additionally, 
2μg of RNA isolated by the procedure described above was substituted for cDNA in a 
real time PCR reaction to confirm that there were no genomic DNA contaminants in the 
RNA samples. Both negative controls showed no amplification after 35 cycles. 
Computer-calculated cycle numbers at which amplified DNA surpassed 
fluorescence threshold were normalized and contrasted to determine relative gene 
expression across treatment groups.  Low cycle numbers signified higher initial amounts 
of cDNA or greater gene expression.  All samples were run in triplicate, and threshold 
values were averaged to determine cycle threshold (CT) values.  Change in threshold 
(dCT) was calculated for each sample by subtracting co-amplified 18s CT values from the 
CT values for genes of interest. 
For graphs, the group with the highest mean dCT value (lowest gene expression) 
per amplified gene target was set to zero and the mean dCT values of the other three 
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groups were set relative to this calibrator (ddCT). The ddCT values were calculated as 
powers of 2 (2
ddCT
), to account for the exponential doubling of the polymerase chain 
reaction. 
 
Statistical Analysis 
Growth data over time were averaged by litter, and linear regression analysis was 
performed by comparison of full and reduced models for body mass and food intake by 
treatment with family-wise Bonferroni correction (Minitab 15 Statistical Software, State 
College PA).  Comparisons of group-by-group reduced and full models were also 
performed with family-wise and post hoc Bonferroni corrections. 
Anatomical measures and most behavioral measures were compared first using 
one-way ANOVA for control, melatonin, and luzindole animals followed by multiple 
comparisons with Bonferonni post hoc analysis (SPSS 16.0, Chicago, IL).  Morris water 
maze data were analyzed with nonlinear mixed effects modeling via the method of 
Young et al. (2008) (R, R Foundation for Statistical Computing, Vienna, Austria).  Gene 
expression data were compared by Kruskal-Wallis analysis followed by group-by-group 
Wilcoxon analysis with Bonferroni correction (SPSS).  Ideally, studies examining 
prenatal effects on litters should use litter averages as the sample unit (Krinke 2000).  
Given that the present data include only 3-4 litters per treatment group, it was decided to 
use individual young as sample units for most measures in this report.  Our final study for 
publication from this data will include at least 8 litters per treatment group.  For all 
measures, statistical significance was set to P < 0.05. 
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RESULTS 
Effects of Altered Prenatal Melatonin Signaling on Litter Size, Litter Composition, 
Growth, and Feeding Patterns 
The effects of administration of vehicle, 5 mg/kg melatonin, or 5mg/kg luzindole 
to pregnant dams from days 14-18 of gestation on litter size, litter sex composition, and 
birth body mass of male and female pups are indicated in Table 2.  Treatment had no 
significant effect on litter size, although this measure was approaching significance 
[F(2,8)=4.078, P=0.060] for a reduction in litter size for the melatonin-treated dams 
compared to luzindole-treated dams [P=0.085].  No significant difference was found 
between litters for male to female pup ratio [F(2,8)=0.333, P=0.726] or for average male 
body mass [F(2,8)=0.511, P=0.618] and average female body mass [F(2,8)=0.332, P=0.727] 
per litter. 
Body mass gain and food intake for male rat litters treated prenatally with vehicle, 
melatonin, or luzindole is shown in Figure 6.  The body mass curve for litters treated 
prenatally with melatonin was significantly different from litters treated prenatally with 
vehicle or luzindole [Overall reduced model to overall full model [F(6,174)=5.0564, 
P=0.00075]; reduced control and melatonin model to full control and melatonin model 
[P=0.00171]; reduced control and luzindole model to full control and luzindole model 
[P=1.00]; reduced melatonin and luzindole model to full melatonin and luzindole model 
[P=0.01084]].  In addition, prenatal treatment was not found to have a significant effect  
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Table 2.  Litter size, ratio of male pups to female pups per litter, and average body mass of male and female 
pups per litter for dams treated with vehicle, 5 mg/kg melatonin, or 5 mg/kg  luzindole during  days 14-18 of 
gestation 
----------------------------------------------------------------------------------------------------------------------------------------------------------------           
 
Litter Size Male Pups/                      Average Male Mass        Average Female Mass  
________                   (Pups)       _____Female Pups          _______(g/pup per litter)__________(g/pup per litter) ___  
 
Control (CON) 14.3 ± 0.9 0.88 ± 0.07           12.7 ± 1.0           12.3± 1.2             
 
Melatonin (MEL) 11.8 ± 0.6 0.9 ± 0.2   13.5 ± 0.9  12.8 ± 1.0    
 
Luzindole  (LUZ) 14.8 ± 0.9 1.1 ± 0.2   11.8 ± 1.5  11.5 ± 1.3 
 
 
CON-MEL-LUZ P=0.060  P=0.726   P=0.618   P=0.727 
 
CON-MEL P=0.197  P=1.00   P=1.00   P=1.00 
 
CON-LUZ P=1.00  P=1.00   P=1.00   P=1.00 
 
MEL-LUZ  P=0.085  P=1.00   P=1.00   P=1.00 
 
________________________________________________________________________________________________ 
Values are means ± SEM. Differences between groups (control-melatonin-luzindole) were determined using one-way 
ANOVA. Significant differences were further analyzed using multiple comparison tests and Bonferroni post hoc analysis.  
Values for litters from dams treated with vehicle, 5 mg/kg melatonin, or 5 mg/kg luzindole during days 14-18 of gestation 
were compared.  *** P < 0.001, ** P < 0.01, * P < 0.05 means are significantly different from control. 
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Figure 6.  Average body weights (a) and food intake (c) of male rats treated 
prenatally with vehicle, melatonin, or luzindole.  Weight and food intake of 11 litters 
[Control n=3, Melatonin n=4, Luzindole n=3] was averaged from weaning at postnatal 
day (PD) 21 to after PD120.  Overall reduced and full regression models with family-
wise Bonferroni corrections were fit to data and compared for significance followed by 
group-by-group comparisons with additional group-by-group Bonferroni corrections 
(b,d).  Litters treated with prenatal melatonin were found to have body mass curves 
significantly different from controls and luzindole-treated litters [[** P<0.01], 
[*P<0.05]]; however, prenatal treatment was not found to have a significant effect on 
food intake. 
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on food intake curves of litters [Overall reduced model to overall full model 
[F(8,154)=2.0693, P=0.3832]. 
As summarized in table 3, prenatal treatment had no significant impact on 
percentage body fat [F(2,61)=0.157, P=0.855], left hippocampus mass [F(2,60)=0.902, 
P=0.411], right hippocampus mass [F(2,60)=0.432, P=0.651], or left hippocampus mass to 
right hippocampus mass ratio [F(2,60)=0.105, P=0.901]. 
 
Effects of Altered Prenatal Melatonin Signaling on Adult Behavior 
Exposure to melatonin or luzindole in utero did not have a significant impact on 
adult male rat behavior in the forced swim test (Figure 7).  Prenatal treatment did not 
affect total distance traveled [F(2,58)=0.887, P=0.418], number of fecal boli produced 
[F(2,58)=0.593, P=0.556], time spent immobile [F(2,58)=0.570, P=0.569], or number of 
immobile episodes [F(2,58)=0.1864, P=0.427].  Although the results for the effects of 
prenatal treatment on turn preference were not significant, a trend was indicated 
[F(2,58)=2.826, P=0.067] for a greater right turn preference for male rats exposed to 
melatonin prenatally [p=0.066]. 
The impact of prenatal treatment on adult male rat behavior in the open field test 
was dramatic (Figure 8).  Although treatment did not have a significant impact on time 
spent in the center of the arena [F(2,61)=0.769, P=0.468] or turn preference [F(2,61)=0.681, 
P=0.510], significant effects were observed for total distance traveled [F(2,61)=4.586, 
P=0.014], time inactive [F(2,61)=4.920, P=0.010], time rearing [F(2,61)=4.175, P=0.020], 
time grooming [F(2,61)=5.470, P=0.007], number of corner entries [F(2,61)=4.938,  
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Table 3.  Percent body fat, left and right hippocampus mass, and ratio of left hippocampus mass to right 
hippocampus mass at sacrifice for male rats treated prenatally with vehicle, melatonin, or luzindole  
---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Percent Body Fat         Left Hippocampus Right Hippocampus   Left Hippocampus/Right 
________                   (fat/body mass)     _______Mass (mg)____________Mass (mg)_______Hippocampus Mass___  
 
Control (CON)       3.54 ± 0.16  75 ± 3                    74.8 ± 1.8          1.01± 0.04             
 
Melatonin (MEL)       3.4 ± 0.3  76 ± 3                    75 ± 2           1.03± 0.03      
 
Luzindole  (LUZ)       3.46 ± 0.14  72.4 ±1.3                     72.8 ± 1.5          1.01±0.03   
 
 
CON-MEL-LUZ       P=0.855  P=0.411                    P=0.651          P=0.901   
 
CON-MEL       P=1.00  P=1.00                    P=1.00           P=1.00  
 
CON-LUZ       P=1.00  P=1.00                    P=1.00           P=1.00 
  
MEL-LUZ        P=1.00  P=0.606                    P=1.00           P=1.00   
________________________________________________________________________________________________ 
Values are means ± SEM. Differences between groups (control-melatonin-luzindole) were determined using one-way 
ANOVA. Significant differences were further analyzed using multiple comparison tests and Bonferroni post hoc analysis.  
Values at sacrifice for male rats treated with vehicle, melatonin, or luzindole prenatally were compared.  Percent body fat 
was found by summing masses of abdominal, gonadal, and retroperitoneal fat deposits in grams and dividing by total 
body mass in grams.*** P < 0.001, ** P < 0.01, * P < 0.05 means are significantly different from control. 
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Figure 7.  The effects of prenatal melatonin or luzindole on adult male rat behavior 
in the forced swim test.  Prenatal treatments were not found to have a significant effect 
on total distance traveled (a), fecal boli (b), immobile time (c), immobile episodes (d), 
and turn preference (e); however, turn preference was approaching significance 
[F(2,58)=2.826, P=0.067] with rats exposed prenatally to melatonin treatment showing a 
trend toward increased preference for turning right compared to controls [P=0.066].  Data 
are expressed as means + SE [Control n=16, Melatonin n=17, luzindole n=28].  Statistical 
differences were determined using one-way ANOVA for the effects of prenatal treatment 
followed by multiple comparison testing using Bonferroni post hoc analysis. 
42 
 
 
43 
 
Figure 8.  The effects of prenatal melatonin or luzindole on adult male rat behavior 
in the open field test.  Prenatal treatment did not have a significant impact on time spent 
in center of arena (e) or turn preference (h).  Prenatal treatment did significantly affect 
total distance traveled (a), inactive time (b), rearing time (c), number of corner entries (f), 
and fecal boli (g) [*P<0.05] in addition to grooming time (d) [**P<0.01].  Data are 
expressed as means + SE [Control n=18, Melatonin n=18, luzindole n=28].  Statistical 
differences were determined using one-way ANOVA for the effects of prenatal treatment 
followed by multiple comparison testing using Bonferroni post hoc analysis. 
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P=0.010], and number of fecal boli produced [F(2,61)=4.070, P=0.022].  In particular, rats 
exposed to luzindole traveled significantly less distance than controls [P=0.013] and 
produced significantly more fecal boli [P=0.033].  In addition, rats treated with luzindole 
prenatally spent significantly more time inactive [P=0.023 control, P=0.050 melatonin] 
and grooming [P=0.029 control, P=0.018 melatonin] and made significantly fewer entries 
to the corners [P=0.042 control, P=0.026 melatonin] compared to controls and melatonin-
exposed animals.  Moreover, animals subjected to melatonin prenatally exhibited rearing 
behavior for a significantly greater duration than control [P=0.045] and luzindole rodents 
[P=0.036]. 
In the elevated plus maze, adult male rat behavior was differentially altered by 
prenatal treatment (Figure 9).  Prenatal treatments had no significant effects on total 
distance traveled [F(2,60)=1.467, P=0.239], time inactive [F(2,60)=1.625, P=0.205], time 
rearing [F(2,60)=0.005, P=0.995], percentage of open arm entries number [F(2,60)=0.0822, 
P=0.444], percentage of closed arm entries [F(2,60)=1.407, P=0.253], percentage of central 
platform entries [F(2,60)=2.000, P=0.144], and number of fecal boli [F(2,60)=0.396, 
P=0.675].  However, rats exposed to prenatal melatonin showed a significantly stronger 
right turn preference [F(2,60)=4.761, P=0.012] than luzindole rodents [P=0.012] with a 
trend toward an augmented right turn preference relative to controls [P=0.080].  In 
addition, a trend was observed for grooming time [F(2,60)=3.101, P=0.052] such that 
luzindole-treated animals approached increased grooming time [P=0.058] in relation to 
melatonin-exposed subjects. 
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Figure 9.  The effects of prenatal melatonin or luzindole on adult male rat behavior 
in the elevated plus maze.  Prenatal treatment did not have a significant impact on total 
distance traveled (a), time spent inactive (b), time spent rearing (c), percentage open arm 
entries (e), percentage closed arm entries (f), percentage central platform entries (g) or 
number of fecal boli produced (h).  Grooming time [F(2,60)=3.101, P=0.052] was 
approaching a significant effect for prenatal treatment such that luzindole animals 
displayed a trend toward increased grooming time [P=0.058] relative to melatonin 
subjects.  Rats exposed to melatonin prenatally displayed a significantly stronger right 
turn preference than luzindole rodents [*P<0.05] (i).  Data are expressed as means + SE 
[Control n=17, Melatonin n=18, luzindole n=28].  Statistical differences were determined 
using one-way ANOVA for the effects of prenatal treatment followed by multiple 
comparison testing using Bonferroni post hoc analysis. 
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Prenatal treatment also significantly changed performance in the learning phase of the 
Morris water maze but not in the memory phase (Figure 10).  Overall nonlinear mixed 
effects modeling revealed a significant difference for the slope of the learning curve 
[F(2,263)=12.52689, P<0.0001] but not for the intercept [F(2,263)=2.07505, P=0.1276] as a 
result of prenatal treatment.  T-test comparison by treatment groups with Bonferroni 
corrections revealed that rats administered luzindole prenatally had learning curves with 
slopes significantly reduced compared to controls [P=0.0015] and melatonin-treated 
animals [P<0.0003].  No significant differences were found for latency to platform 
[F(2,61)=0.231, P=0.794], mean distance from platform [F(2,61)=0.153, P=0.858], time 
spent in memory region [F(2,61)=0.405, P=0.669], total distance traveled [F(2,61)=0.775, 
P=0.465], or turn preference [F(2,61)=0.857, P=0.429]. 
 
Effects of Altered Prenatal Melatonin Signaling on Hippocampal Gene Expression 
Due to outliers and observable skew in the data sets, nonparametric Kruskal-
Wallis tests were used to analyze gene expression data (Figure 11).  Analysis of gene 
expression during two distinct time periods (0000 hr vs. 1200 hr) failed to produce a 
significant difference in circadian expression of the genes examined (data not shown), 
although MAP2 expression displayed circadian behavior closest to significance [P= 
0.1547].  In contrast, Kruskal-Wallis analysis revealed a significant effect of prenatal 
treatment on expression of BDNF [P=0.043] and MAP2 [P=0.048].  Group-by-group 
Wilcoxon comparisons with Bonferroni corrections found a significant increase in 
expression of BDNF in melatonin rats compared to controls [P=0.0425], but the increase  
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Figure 10.  The effects of prenatal melatonin or luzindole on adult male rat behavior 
in the Morris water maze.  Linear mixed effects modeling showed that prenatal 
treatment produced a decrease in slope of the learning curve for luzindole-treated animals 
relative to controls [**P<0.01] and melatonin-treated animals [***P<0.001] but had no 
significant impact on intercept of the learning curve (a).  No significant effects of 
prenatal treatment were observed in the memory phase of the test (b-f).  Data are 
expressed as means + SE [Control n=18, Melatonin n=18, luzindole n=28].  Statistical 
differences for the learning phase were determined by nonlinear mixed effects modeling.  
Statistical differences for the memory phase were determined using one-way ANOVA for 
the effects of prenatal treatment followed by multiple comparison testing using 
Bonferroni post hoc analysis. 
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Figure 11.  The effects of prenatal melatonin or luzindole on adult male rat 
hippocampal gene expression.  Relative cycle number to fluorescence for hippocampal 
cDNA during real-time PCR with primers for 5HT1A, 5HT1B, 5HT2A (b); BDNF, 
MAP2, spinophilin (SPN) (d); and growth hormone receptor (GHR), MEL1A, MEL1B 
(f); with 18s is indicated in representative kinetics curves.  Relative gene expression for 
all genes assayed is also indicated (a,c,e).  Prenatal treatment had a significant effect on 
expression of BDNF and MAP2 [*P<0.05] and produced a trend toward significance for 
MEL1A expression [P=0.078].  In particular, a significant increase in expression of 
BDNF in rats treated prenatally with melatonin relative to controls [*P<0.05] was found.  
Data are expressed as means + SE [Control n=18, Melatonin n=18, luzindole n=28].  
Statistical differences were determined using Kruskal-Wallis for the effects of prenatal 
treatment followed by group-by-group Wilcoxon comparisons with Bonferonni 
corrections. 
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in expression of BDNF in melatonin animals compared to luzindole animals was 
not significant [P=0.1317].  In addition, group-by-group comparison revealed a trend 
toward increased expression of MAP2 in luzindole rats compared to controls [P=0.0526].  
Finally, a trend for a treatment effect on MEL1A expression [P=0.078] was also 
observed. 
 
DISCUSSION 
 Our study was designed to test the effects of altered prenatal melatonin signaling 
on growth patterns, behavior, and hippocampal gene expression in adult male rats.  The 
limited existing research on the postnatal effects of altered prenatal melatonin signaling 
precludes a definitive conclusion; however, data from a series of diverse studies on the 
functions of melatonin in general provide a context for our findings. 
 
Melatonin and Body Growth 
As predicted, prenatal melatonin had a significant impact on growth patterns of 
offspring.  An upward shift in growth curve and accelerated growth was observed for 
melatonin-treated animals compared to luzindole-treated animals and controls.  These 
alterations were not accompanied by a change in body fat at sacrifice which suggests that 
this difference was not the result of increased fat deposition.  Growth hormone has been 
shown to increase muscle and skeleton mass and to reduce fat mass in female pigs 
(Sørensen et al. 1996), and growth hormone administration to 19- to 21-month-old 
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Sprague-Dawley rats induced greater protein synthesis (Sonntag et al. 1985).  Thus, it is 
possible that the growth changes measured in our animals may be due to alterations in 
growth hormone secretion. 
The direction of the change in growth patterns, however, is difficult to interpret 
given the contradictory findings in the literature.  Administration of melatonin (4 μg/mL) 
in drinking water for 12 weeks to adult Sprague-Dawley rats produced sex-dependent 
metabolic effects (Bojková et al. 2008).  In particular, in adult males, exposure to excess 
melatonin reduced body weight, liver glycogen, and serum insulin and increased 
concentrations of corticosterone, serum and heart muscle cholesterol, heart muscle 
phospholipids, and indicators of oxidative stress.  Interestingly, the increase in growth 
hormone secretion elicited by administration of serotonin (10 mg/kg) to 80-day-old 
Wistar rats was blocked by concomitant administration of melatonin (80 mg/kg) (Smythe 
et al. 1973).  Similar antagonistic effects for both melatonin and serotonin on growth 
hormone secretion were also observed in 21-28-year-old human male subjects (Smythe et 
al. 1974 b).  Thus, it appears that melatonin may mediate reduction in growth hormone 
secretion and body mass in adult rats. 
However, melatonin’s effect on growth may be different when administered 
during prenatal development or lactation.  Injection of meadow vole Microtus 
pennsylvanicus dams with 10 μg melatonin per animal daily during pregnancy reduced 
offspring weight in both sexes and delayed sexual development only in male offspring 
(Lee et al. 1989).  In contrast, melatonin treatment during lactation increased body 
growth from postnatal day 21 until sacrifice at postnatal day 49 for males and females.  In 
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the male rat, pineal and serum melatonin levels at the middle of the dark phase of the 
circadian cycle were found to rise during postnatal days 1 to 9, remain high during 
postnatal days 11 to 17, and lower after day postnatal day 21 (Tang et al. 1988).  
Moreover, the drop in melatonin levels after postnatal day 21 was found to be 
independent of weaning.  Although we altered only prenatal melatonin levels in our 
experimental animals, we had hypothesized that treatments would permanently alter 
function of the circadian circuit causing increased endogenous melatonin production 
postnatally in melatonin-treated animals and reduced melatonin secretion postnatally in 
luzindole treated animals.  The observed augmentation of growth in our melatonin-treated 
rats may not be consistent with immediate effects of prenatal treatment on growth 
patterns of offspring but may be consistent with augmented postnatal function of the 
circadian circuit.  In particular, our data may suggest increased melatonin levels in 
offspring during the period of lactation as a result of prenatal melatonin treatment. 
 
Melatonin and Behavior 
As predicted, prenatal treatments in our study produced differential behaviors in 
adult offspring.  These differences are not fully consistent with existing literature since 
increases or decreases in melatonin levels in adult rodents produce differential behaviors 
based on experimental design.  For example, depression of locomotor activity in adult 
male golden hamsters was observed after intraperitoneal administration of at least 30 μg 
melatonin/kg for 5 days (Golombeck et al. 1991).  This effect on behavior was found to 
be lowest at midnight and could be blunted by administration of a benzodiazepine.  A 
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reduction in locomotor activity, rears, and entries into the unfamiliar zone of the free 
exploratory test was also observed in adult C3H/He mice (Kopp et al. 1999).  However, 
this change in behavior was measured in animals treated with 10 mg melatonin/kg per 
day at the beginning of the dark phase during and immediately after a 3-week stress 
period and then exposed to a chronic mild stress procedure. 
Adult melatonin treatment has also been shown to elicit differential behavioral 
patterns by sex.  Administration of melatonin (4 μg/mL) in drinking water for two weeks 
was associated with an increase in climbing in the forced swim test in thirteen-month-old 
Long Evans male rats (Brotto et al. 2000).  However, both treated and control females 
displayed augmented activity in both the forced swim test and open field test compared to 
males.  Among the females studied, melatonin-exposed animals exhibited increased 
immobility on the first day of the forced swim test.  This study also showed that 
melatonin exposure was associated with increased ambulation in the open field test and 
reduced swimming in the forced swim test in both sexes.  No significant change in 
behavior in the forced swim test was observed for either treatment in our study compared 
to the significant changes observed by Brotto et al.  Moreover, the significant change in 
behavior of adult male animals exposed prenatally to melatonin and tested in the open 
field test in our study is different from the changes in response to adult melatonin 
treatment in the Golombek et al., Kopp et al., and Brotto et al. studies.  More specifically, 
our melatonin-exposed animals displayed augmented rearing compared to animals treated 
with luzindole in utero or controls but not increased distance traveled relative to controls.  
Given the increased ambulation but not rearing in the open field test of animals treated 
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with melatonin in adulthood in the Brotto et al. study and the reduction in locomotor 
activity by Golombek et al. and Kopp et al., we suggest that prenatal and postnatal 
melatonin changes may elicit differential behavioral effects in adult animals. 
 Melatonin not only produces differential effects by sex but also by the receptor 
subtype via which it elicits signaling.  MEL1A receptor knockout mice of both sexes 
displayed impaired sensorimotor gating as evidenced by the prepulse inhibition test (Weil 
et al. 2005).  These mice also showed decreased preference for the center of the arena in 
the open field test.  In addition, they spent more time immobile in the forced swim test.  
Female wild-type mice showed greater locomotor activity than males in the open field 
test, but this difference between sexes did not exist in knockout mice.  In another study, 
4- to 5-week-old C3H/HeN mice administered melatonin (30 mg/kg) did not show a 
significant change in behavior in the forced swim test while luzindole (30 mg/kg) 
reduced immobility time in the forced swim test with a greater effect at midnight than at 
noon (Dubocovich et al. 1990).  Moreover, administration of 30 mg/kg melatonin with 10 
mg/kg luzindole blunted the effects of luzindole on behavior.  In subsequent study using 
MEL1A-knockout and MEL1B-knockout C3H/HeN mice, it was found that this effect of 
luzindole on forced swim test behavior was mediated via the MEL1B receptor (Sumaya 
et al. 2005).  Since no effects of treatment were observed in the forced swim test for our 
subjects, our data suggest that activity of MEL1B receptors are not significantly affected 
by treatment.  In contrast, the augmented fear response of luzindole animals in the open 
field test as indicated by increased time inactive suggest a possible role for MEL1A 
receptor dysregulation in these animals.  Interestingly, rats exposed prenatally to 
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luzindole in our study outperformed both melatonin-treated and control animals in the 
learning phase of the forced swim test by finding the platform more quickly.  Since 
MEL1B receptor knockout mice displayed impaired spatial learning in the Morris water 
maze (Larson et al. 2006), our data from luzindole-exposed offspring in the learning 
phase of the forced swim test may also preclude involvement of MEL1B receptors in the 
behavioral differences observed in our subjects.  
In addition to postnatal changes in melatonin signaling via administration of 
melatonin agonists or antagonists in adulthood and lifelong changes in melatonin 
signaling by receptor knockout, prenatal alterations of melatonin signaling have also been 
found to impact adult behavior.  Maternal pinealectomy of Siberian hamsters produced 
increased immobility in the forced swim test and rearing behavior in the open field test of 
adult male offspring (Workman et al. 2008).  Moreover, this study found that postnatal 
pinealectomy of adult males augmented locomotor activity in the open field test.  Our 
results, however, are inconsistent with this study.  No significant differences in forced 
swim test behavior in our prenatally animals were observed compared to the increased 
learned helplessness in response to reduced prenatal melatonin signaling in the Workman 
et al. study.  In addition, melatonin-treated animals in our study displayed increased 
rearing and locomotor activity in the open field test relative to luzindole-treated animals.  
Luzindole treatment would be expected to have reduced effectiveness of melatonin 
signaling during early development of our rats.  Since the subjects in the Workman et al. 
study showed increased locomotor activity in response to reduced melatonin signaling 
following postnatal pinealectomy, it is possible that prenatal and postnatal effects of 
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melatonin on signaling are significantly different.  Moreover, the use of pinealectomy or 
removal of endogenous melatonin in their study versus exogenous hormone or hormone 
antagonist treatment in ours may have produced differential effects.  Species differences 
may also be important in this case. 
Additional studies designed to alter the intrauterine environment included 
melatonin administration to spontaneously hypertensive rat (SHR) dams.  SHR animals 
are considered a model of attention deficit hyperactivity disorder (Sagvolden 2000) 
which is associated with heightened locomotor activity.  SHR dams given water 
containing melatonin (20 μg/mL) during gestation and lactation were found to have 
offspring that displayed reduced locomotor activity and rearing behavior as compared to 
control SHR offspring (Kim et al. 2002).  Our findings differ from the Kim et al. study in 
that prenatal melatonin treatment reduced locomotor activity in the forced swim test in 
their animals while our animals exposed to melatonin in utero showed no significant 
difference from controls.  In addition, their animals also displayed reduced locomotor 
activity in the open field test in response to prenatal treatment with melatonin while our 
melatonin animals showed increased locomotor activity.  However, since they used a 
strain of rats considered to be a model of a psychiatric disorder, it is possible that their 
animals responded differently to melatonin treatment than wild type rats. 
Animals treated prenatally with luzindole in our study displayed significantly 
greater grooming than melatonin-treated animals and controls.  Previous studies suggest 
that increased grooming behavior may be a result of increased stress response in these 
animals.  For example, administration of the corticotrophin releasing factor 1 (CRF1) 
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receptor agonist MJL-1-109-2 (1 nM) to adult male Wistar rats produced increased 
freezing, grooming, and mounting behaviors (Zhao et al. 2007).  Administration of CRF1 
to adult male Wistar rats also induced an increase in hippocampal free corticosterone 
levels and a reduction in serotonin (de Groote et al. 2005).  Further data collection will 
include radioimmunoassay analysis of serum for basal corticosterone levels in our 
animals. 
In contrast to our luzindole-exposed adult offspring, animals treated prenatally 
with melatonin in our study displayed significantly increased rearing behavior.  A first 
review of evidence for a role of the septo-hippocampal system in rearing behavior 
concluded, however, that the role of the hippocampus in exploratory rearing behavior is 
still poorly understood (Lever et al. 2006).  The authors cite various lines of evidence 
implicating the involvement of projections from the dentate gyrus to the CA3 region of 
the hippocampus and also importance of the CA1 region in rearing behavior in reference 
to spatial learning, but admit that the specific functions of these regions are highly 
context dependent.  Thus, the increased rearing behavior of animals exposed to melatonin 
prenatally in our study suggests a potential role for prenatal melatonin in adult 
hippocampal function. 
Interestingly, in our melatonin-exposed offspring, a significant right turn 
preference was observed in the elevated plus maze with a trend toward significance in the 
forced swim test.  A stronger right-turn preference was also found in adult Long-Evans 
hooded rats in response to neonatal novelty (Tang et al. 2003).  Moreover, these animals 
showed increased social memory and lower basal plasma corticosterone levels compared 
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to controls after neonatal novelty exposure.  Abnormal brain lateralization has also been 
associated with autism (Escalante-Mead et al. 2003) and schizophrenia (Sommer et al. 
2001) in humans.  In our study, measurements of left hippocampal mass compared to 
right hippocampal mass suggest a slight increase in animals treated prenatally with 
melatonin; however, the method of measurement may have been too imprecise to detect 
significant mass differences.  In addition, other studies suggest that volume 
measurements are preferred to those of mass.  Thus, additional procedures, such as 
staining and sectioning of brain tissue, may be required to observe possible lateralization 
differences in additional cohorts of rats reserved for this purpose.  Given the potential 
importance of brain lateralization in adult psychopathology, further research to confirm a 
role for melatonin in brain lateralization is warranted.   
 
Melatonin and Gene Expression 
 Our molecular data suggest a connection between prenatal melatonin signaling 
and adult hippocampal gene expression.  Moreover, evidence in the literature also 
supports a significant molecular impact of maternal melatonin levels on offspring.  For 
example, pups of pinealectomized Wistar rat dams displayed reduced expression of 
melatonin receptors in their brains at postnatal day 9 (Zitouni et al. 1995).  MEL1A 
receptor concentrations were reduced and clock gene expression oscillations were altered 
in the SCN of capuchin monkey fetuses of pinealectomized mothers, and the effect of 
pinealectomy on these variables could be ameliorated by melatonin administration 
(Torres-Farfan et al. 2006).  
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In our study, augmentation of prenatal melatonin signaling significantly increased 
adult hippocampal BDNF expression in adult offspring.  Recent studies from other in 
vivo models have also found links between melatonin receptor signaling and BDNF 
expression.  Cerebellar granule cells from 5-day old MEL1B knockout CH3 mice showed 
increased expression of BDNF in response to melatonin administration in vivo and in 
vitro compared to those from wild-type and MEL1A-knockout mice (Imbesi et al. 2008 
a).  In addition, nanomolar concentrations of the melatonin receptor agonist, ramelteon, 
increased expression of BDNF protein without increasing mRNA levels in cerebellar 
granule cells from all MEL1A-knockout, MEL1B-knockout, and control mice (Imbesi et 
al. 2008 b). 
Results from in vitro cell culture studies suggest that melatonin regulates the 
expression of its own receptors.  For example, in CHO cell lines expressing high levels of 
MEL1A receptors, a significant reduction in these receptors at the cell surface was 
detected 1 hour after treatment with melatonin, but total cellular concentration of the 
MEL1A receptor was unaffected (Kokkol et al. 2007).   In contrast, this same study found 
that CHO cell lines expressing high levels of melatonin MEL1A receptors decreased total 
cellular MEL1A receptor concentrations in response to administration of luzindole at 
both 1 and 72 hours after treatment, and expression at the cell surface was increased at 72 
hour after treatment.  Additional studies have shown that MEL1A receptors are also 
expressed in the immortalized C17.2 dopaminergic neural stem cell line, and 
administration of melatonin to these cells increased release of glial-cell derived 
neurotrophic factor (Niles et al. 2004).  A later study showed that melatonin treatment of 
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these cells—which do not express MEL1B receptors—promoted neurite outgrowth, 
increased expression of the neural stem cell marker nestin, histone deacetylases HDAC 3, 
HDAC 5, and HDAC 7, and augmented histone H3 acetylation (Sharma et al. 2008).  
Administration of valproic acid, a mood stabilizer, to rat C6 glioma cells for 24 hours 
increased expression of MEL1A receptor mRNA and protein in a dose-dependent manner 
and this increase in MEL1A receptor was associated with an increase in BDNF, GDNF, 
and histone deacetylase (HDAC) mRNA levels (Castro 2005).  In addition to influencing 
the expression of neurotrophic factors, melatonin been found to inhibit apoptosis at the 
mitochondrial level via MEL1A and MEL1B receptor signaling in U937 cells (Radogna 
et al. 2008).  Melatonin supplementation has also been shown to affect hippocampal cells 
directly.  For example, melatonin promoted survival of neural precursor cells from the 
hippocampi of adult female C57BL/6 mice, and this effect could be diminished by 
administration of luzindole (Ramírez-Rodríguez et al. 2009).   
In addition to these cell culture studies, in vivo evidence suggests a role for 
melatonin in hippocampal cell maintenance.  Ramírez-Rodríguez et al. (2009) found that 
administration of 8 mg/kg melatonin intraperitoneally to adult mice promoted survival of 
neural precursor cells, but maturation and proliferation of these cells was unaffected.  The 
hippocampi of rats treated prenatally with melatonin in our study approached significance 
for increased MEL1A expression relative to controls and luzindole-treated animals while 
simultaneously displaying a significant increase in BDNF expression.  Thus, our data 
suggest an in vivo connection between MEL1A receptor signaling and BDNF expression 
in the hippocampus and support a role for melatonin in hippocampal cell maintenance. 
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Melatonin has been found to have various antioxidative properties that are 
independent of its receptor-mediated effects (for reviews see Hardeland 2005; Ortiz et al. 
2008).  Pretreatment with 2 mg/kg melatonin subcutaneously was found to counteract 
oxidative damage by methamphetamine in the neonatal Wistar rat prefrontal cortex, 
nucleus accumbens, and dorsal striatum (Kaewsuk et al. 2009).  These antioxidant 
properties also extend to melatonergic drugs.  Melatonin and related compounds have 
been found to protect rat synaptosomal membranes from oxidative damage (Millán-Plano 
et al. 2010).  In the ABTS assay, both melatonin and luzindole at the concentration of 10 
μM showed greater antioxidant capability compared to a similar concentration of ascorbic 
acid (Mathes et al. 2008).  Luzindole at a dose of 800 μM prevented lipid peroxidation 
induced by iron and LPS in F344N rat brain tissue homogenates (Requintina et al. 2007). 
The antioxidant properties of both melatonin and luzindole, however, suggest a 
possible complication with our design.  Given that the DMSO vehicle used has been 
found to produce apoptosis of cells in the developing mouse brain at 0.3 mL/kg, the 
lowest dose examined (Hanslick et al. 2009), it is possible that any deficits produced by 
the vehicle can be ameliorated by either melatonin or luzindole.  In our study, we used 
DMSO at a concentration of 0.1 mL/kg per day.  Although this dose is less than that used 
by Hanslick et al. (2009), use of DMSO as a vehicle allows for the possibility that some 
predicted deficits in either treatment group relative to controls may be hidden by the 
antioxidant properties of the treatment.    
Prenatal treatment in our study also altered mRNA expression for MAP2.  
Previous studies suggest a role for MAP2 in the structure and function of hippocampal 
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neurons.  For example, hippocampal cells from MAP2 knockout mice cultured for 3 
weeks displayed reduced dendritic length compared to cells from wild-type animals 
(Harada et al. 2002).  MAP2 expression in the hippocampus has been found to change in 
response to learning tasks.  In particular, MAP2 was down-regulated in the hippocampus 
of adult male Wistar rats after exposure to the Morris water maze relative to controls 
exposed to swimming or no testing 1 or 24 hours before sacrifice (Cavallaro et al. 2002).  
Conversely, MAP2 protein and mRNA expression in the hippocampus was positively 
correlated with learning and memory performance in the Morris water maze in male 
Wistar rats exposed to cerebral hypoperfusion for 20 weeks (Liu et al. 2005).  Our data 
indicate that rats treated prenatally with luzindole displayed the greatest relative 
expression of MAP2 mRNA and augmented performance in the learning phase of the 
Morris water maze.  Since the MAP2 protein is considered a marker of dendritic density, 
a link between this protein and learning is logical.  Given that the direction of change in 
MAP2 expression is the same in both melatonin and luzindole-treatment groups, it is 
possible that some of the treatment effects may be due to the antioxidant properties of the 
drugs.  It is also possible that hippocampal cell plasticity is increased in both groups for 
different reasons.  Examination of relative mRNA levels for additional genes—including 
the marker of hippocampal neurogenesis, doublecortin (DCX) (Brown et al. 2003)—
would help to further explain these learning differences and is underway in our lab.  It is 
worth noting, however, that increased expression of MAP2 has been found in the 
hippocampus of individuals with schizophrenia (Cotter et al. 2000) and thus can be a 
marker of psychopathology. 
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Although indications of an increase in anxiety-related behavior such as increased 
inactive time and grooming in the open field test were identified in animals exposed to 
luzindole prenatally, it is surprising that none of the 5HT receptor genes showed 
differential expression in response to treatment.  It is possible that the expression of these 
serotonin receptors is altered only after a stressful challenge, and this possibility will be 
studied in a future cohort of our prenatally exposed animals.  Future research will also 
entail radioimmunoassay of serum melatonin, growth hormone, and cortisol levels to 
examine the effects of prenatal treatment on adult hormone secretion.  Moreover, despite 
a significant effect of prenatal treatment on MAP2 expression, no change in expression of 
SPN was observed.  Thus, our present data suggest that the prenatal treatments had an 
impact on overall dendrite structure but not the fine structure of dendritic spines given the 
localization of spinophilin to dendritic spines but MAP2 to entire dendrites.  Also, despite 
the effects of melatonin on growth curve shape, no significant differences in GHR 
expression were observed. 
Given that we have only extracted mRNA from the left hippocampi of our 
subjects, we cannot make any conclusions regarding lateralization at the molecular level 
at this time.  In other studies, however, the hippocampus of rats showed differential 
norepinephrine, serotonin, and choline uptake on the side opposite the direction of turn 
preference in the T maze (Valdes et al. 1981).  Comparisons of gene expression between 
right and left hippocampi will be conducted. 
 
 
67 
 
Model Incorporating the Circadian Circuit in Development 
This study was based on four related hypotheses, although additional research 
beyond this study will be necessary to validate all of them.  First, maternal  melatonin 
secretion helps drive the growth and maintenance of neurons of the fetus.  Some of this 
effect results from cell signaling via cell membrane receptors that specifically bind 
melatonin.  Blockade of these receptors or increased binding of ligand to these receptors 
results in greater or lesser growth of neurons.  This altered neuron growth affects the 
construction of the meshwork of circuits in the developing fetal brain.  In addition to this 
immediate effect on early brain development, changes to the fetal circuit meshwork 
impact future brain growth by providing an abnormal scaffold for later cell migration, 
growth, and connectivity. 
Second, since melatonin receptors are found in high concentrations in the fetal 
hypothalamus, early growth of the SCN is more markedly affected by prenatal melatonin 
concentrations compared to other brain regions.  Given that the SCN functions as the 
circadian pacemaker, altering the development of this brain region permanently affects 
the function of the circadian circuit of an organism.  These permanent changes in the 
circadian circuit result in physiological and behavioral changes in adult organisms 
Third, since the hippocampus develops rapidly during a specific period in the 
third trimester of pregnancy while other brain regions develop more gradually, this brain 
region shows larger changes in response to altered prenatal melatonin levels in late 
gestation than other brain regions.  Because this brain region is particularly plastic 
throughout development and adulthood, improper function of the circadian circuit 
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resulting in aberrant melatonin secretion compounds existing developmental aberrations 
by influencing further postnatal growth, maintenance, and plasticity.  As a result this 
summation of prenatal and postnatal effects of prenatal melatonin on hippocampal 
development, initial pathology of this brain region becomes more pronounced as the 
brain develops through puberty and early adulthood. 
Fourth, since circadian melatonin secretion regulates the release of other 
hormones, permanently altering the circadian circuit causes various changes in circadian 
physiology of neuroendocrine circuits.  In particular, melatonin influences growth 
hormone release.  Since growth hormone is important in various aspects of growth, 
metabolism, and brain function, changes in circadian growth hormone signaling may 
cause subtle aberrations in these processes. In addition, because the circadian circuit and 
the hippocampus also interact with the HPA axis, changes in these brain regions in 
response to alterations of prenatal melatonin signaling will permanently alter HPA-axis 
function. 
  Although these hypotheses are broad, they provide a framework for a model 
involving the circadian circuit in brain development.  Given the numerous interactions of 
the circadian circuit and the HPA axis of mammals and the importance of variation in 
function of both circuits over a 24-hour period, we designate the term 
circadioneuroendocrine axis (CNE) axis.  The CNE axis includes structures of both the 
circadian circuit and HPA axis in addition to hormones released by the pituitary, pineal, 
and other neuroendocrine glands which directly impact brain function and organismal 
behavior in response to environmental stimuli.  Use of this term stresses the necessity of 
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investigating these circuits as a function of time.  Such a framework is required for 
integration of the litany of varied and often contradictory research already conducted in 
the field of neuroscience.  Moreover, future research will need to be conducted precisely 
within such a framework to connect it to existing literature if a holistic understanding of 
brain development and function is to be obtained. 
From this terminology follows a name for our hypothesis regarding the role of the 
CNE axis in brain development and psychopathology: the CNE-axis hypothesis of 
psychopathology.  According to this hypothesis, the magnitude, direction, timing, and 
duration of disturbances of the CNE axis during development determine the resulting 
psychiatric disorder.  This hypothesis does not preclude genetic causation but does 
provide for the incorporation of not only environmental stimuli but also the timing of 
those stimuli relative to endogenous rhythms.  Future research will be necessary, 
however, to discover potential new and integrate existing known critical periods and 
critical disturbances capable of producing outlying developmental trajectories. 
 
PERSPECTIVES AND SIGNFICANCE 
Although our study does not provide definitive support for any of the broad 
hypotheses of our proposed model, our data do support the hypothesis that melatonin 
signaling in utero disturbs neuroendocrine setpoints to produce differential growth, 
behavior, and gene expression in a region of the brain in the male rat that is important in 
human psychopathology.  Because nocturnal rats (Mandera et al. 2003) secrete melatonin 
in profiles that are comparable to those of diurnal organisms, signaling via melatonin 
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receptors in rats is likely to produce different cellular responses compared to those found 
in diurnal mammals.   Comparative studies show that while melatonin exerts certain 
differential effects between nocturnal and diurnal organisms, some of its actions may be 
similar across species (López-Olmeda et al. 2006).  Studies of melatonin functions in 
multiple organisms allow for possible mechanisms in other species to be elucidated and 
for the formulation of further research questions.  Moreover, as the body of literature 
regarding the developmental impacts of melatonin is built, current theoretical frameworks 
of the circadian circuit and its effectors can be further amended to incorporate 
interspecies variations. 
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